MeSH D007943 - hairy cell leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Apotex | Cladribine | Cladribine | 2025-11-24 | |||
| AstraZeneca | Moxetumomab pasudotox | Lumoxiti | 2021-02-08 | |||
| EMD Serono | Cladribine | Mavenclad | 2024-04-11 | 2019-03-29 | ||
| Fresenius Kabi | Cladribine | Cladribine | 2004-04-22 | |||
| Hikma Pharmaceuticals | Cladribine | Cladribine | 2000-02-28 | |||
| Hisun Pharmaceutical (Hangzhou) | Cladribine | Cladribine | 2019-11-25 | |||
| Hospira | Pentostatin | Nipent | 1991-10-11 | |||
| Johnson & Johnson | Cladribine | Leustatin | 1993-02-26 | |||
| Lipomed | Cladribine | Litak | 2004-04-14 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
61%35/57
Phase 2
2%1/50
Phase 3
100%15/15
Approved: 12Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use